Mednet Logo

What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?

Do you prefer single agent PD-1 inhibitor or combination immunotherapy?
Community PollStarted

What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?

16 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University Hospitals
Answered on

This is one of the most debated questions in the melanoma community. We personally prefer using single agent anti-PD1 in the neoadjuvant setting based on the results of the SWOG-1801 study. The recently presented data at ESMO 2023 showed a 97% 2-year RFS in patients with complete pathologic response...

Join for free or sign in to see the full answer